44.7 percent of angiotensin receptor blocker initiators were continuously persistent to original drug class at three years.

Post hoc trial findings support aprocitentan’s potential cardiovascular and kidney-protective effects in patients with chronic kidney disease (CKD) with resistant hypertension.

Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving ...

Early intensive BP control significantly reduces cardiovascular risk in older patients compared with delayed initiation of treatment.

SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing ...

Cardiovascular disease remains a leading global cause of death, and we break down its pathology, risk factors, and the ...

The American Heart Association and the American the College of Cardiology in 2025 issued guidelines to help reduce ...

Al-Gahtani, S. (2026) Review of Literature Investigating the Correlation between Prevalence of Risk Factors Associated with ...

The hypertension drug rilmenidine has been found to slow aging in worms – an effect that, if it translates to humans, could one day help us live longer and stay healthier in old age. Rilmenidine ...

Abstract: This study addresses the impediments of current prescient models by creating a more precise machine learning-based framework for early hypertension expectation. The essential research is to ...